Company Overview
Theravance Biopharma, Inc. functions as a biopharmaceutical entity dedicated to the development and commercialization of therapeutic medicines within the United States, specifically focusing on respiratory treatments such as YUPELRI, a nebulized long-acting muscarinic antagonist designed for the management of chronic obstructive pulmonary disease. Operating within the Healthcare sector and the Biotechnology industry, the company targets specialized therapeutic areas where innovation in drug delivery mechanisms, such as once-daily formulations, is critical for patient adherence and clinical outcomes. The company's current market capitalization stands at $744.88M, supported by an annual revenue of $107.46M and a reported employee count of N/A, which reflects a lean organizational structure typical of biotechnology firms in late-stage development phases. These valuation and revenue metrics indicate that the company holds a niche position in the market, possessing significant value relative to its sales volume but operating with a scale characteristic of specialized biotech entities rather than broad-market pharmaceutical giants.
Financial Health
The company reported a revenue of $107.46M for the trailing twelve months, generating a net income of $105.89M while reporting an EBITDA of $-1,966,000, a disparity that reveals a cost structure where non-cash expenses or significant depreciation and amortization are likely driving the divergence between accounting profit and cash earnings before interest, taxes, and depreciation. Free cash flow is listed as N/A, suggesting that cash flow from operations minus capital expenditures is either negligible or not separately disclosed, which limits the immediate assessment of financial flexibility regarding capital return or organic reinvestment capabilities. The gross margin is 65.2%, indicating that the majority of revenue remains after the direct costs of producing the medicines, while the operating margin of 43.6% and profit margin of 98.5% demonstrate exceptional control over overhead and a highly efficient conversion of revenue to net earnings. Total cash on hand of $315.36M substantially exceeds total debt of $31.76M, and with a debt-to-equity ratio of 10.70, the balance sheet appears conservative regarding leverage despite the high ratio, as the absolute debt load is small relative to cash reserves. The current ratio is 10.93, which indicates a very strong position in short-term liquidity, allowing the company to meet its current liabilities many times over without needing to raise external capital. Return on Equity is 44.8%, signaling highly effective utilization of shareholder equity to generate profits, whereas Return on Assets is -0.5%, reflecting that total assets are generating a slight loss on an accounting basis, likely due to the specific amortization of intangible assets common in biotechnology.
Valuation Assessment
The trailing P/E ratio is 25.79, while the forward P/E is 13.61, and the difference between these two metrics implies that the market expects a significant increase in earnings in the future, as the forward multiple is less than half the trailing multiple. The price-to-book ratio is 2.53, indicating that the market values the company at a 153% premium over its book value, which suggests investors are pricing in high growth potential or intangible assets that are not fully captured on the balance sheet. The price-to-sales ratio is 6.93, and the EV/EBITDA is -227.98, where the negative EV/EBITDA metric suggests that the company's enterprise value is heavily influenced by its net cash position rather than operating profitability in the traditional sense. The 52-week high is $21.03 and the 52-week low is $7.90, and without a specific current price provided in the facts, the range defines the volatility band within which the stock has traded over the last year. The beta value is 0.11, which means the stock's price volatility is significantly lower than the broader market, exhibiting a stability that is uncommon for biotechnology companies and suggests limited sensitivity to general market movements.
Growth & Income
Revenue growth year-over-year is 144.7%, which is an exceptional expansion rate, while earnings growth is N/A, indicating that the current earnings are driven by base-level profitability rather than a year-over-year acceleration of profit growth in the traditional sense. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests all generated earnings back into research, development, and commercialization efforts rather than distributing income to shareholders. The absence of a dividend policy aligns with the life cycle of a biotechnology firm that prioritizes capital allocation toward late-stage investigational assets and product expansion over income distribution. The overall growth and income profile is characterized by explosive top-line revenue expansion supported by highly efficient margins, but lacking traditional income generation through dividends or significant earnings acceleration compared to the revenue surge.